Trinomab’s TNM002 Antitetanus Monoclonal Antibody Filing Accepted for Review in China
China’s Center for Drug Evaluation (CDE) has accepted Trinomab Biotech Co., Ltd.’s market approval filing...
Drug
Eli Lilly Seeks Approval for Pirtobrutinib in China for Relapsed Mantle Cell Lymphoma
Eli Lilly (NYSE: LLY) has submitted a marketing approval application for pirtobrutinib, an oral, non-covalent...
Shenzhen TargetRx’s TGRX-678 Set to Receive Breakthrough Therapy Designation for CML-AP
Shenzhen TargetRx, Inc., a China-based developer of small-molecule kinase inhibitors, is poised to receive breakthrough...
Changchun BCHT Secures NMPA Approval for Freeze-Dried Human Rabies Vaccine Trials
Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has...
Shanghai Pharmaceuticals Gains NMPA Approval for WST04 Clinical Trials in Oncology
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...
Jiangsu Hengrui Seeks NMPA Approval for Camrelizumab-Famitinib Combo in Cervical Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), based in China, has announced that its market...
Antengene Secures NDA Approval for Xpovio in Macau for Advanced Multiple Myeloma
Antengene Corp., Ltd. (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria
Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and...
China Medical System’s Methotrexate Injection Receives NMPA Review for Rheumatoid Arthritis Indication
China Medical System Holdings (CMS; HKG: 0867) has announced that the National Medical Products Administration...
Huadong Medicine Gets NMPA Green Light for Sirolimus Real-World Study in Pediatric Epilepsy
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has received approval from the...
Sino Biopharmaceutical Initiates Phase I Trial for Hepatitis B siRNA Drug TQA3038
Sino Biopharmaceutical Ltd (HKG: 1177), a leading biopharmaceutical company based in China, has announced the...
Jingxin Pharmaceutical’s Didaxini Gains NMPA Approval as Category 1 Drug
Jingxin Pharmaceutical Co., Ltd (SHE: 002020), a Chinese pharmaceutical company, has announced that it has...
Biocytogen Pharmaceuticals Secures US Patent for Fully Human Antibody Mice Platform RenMab
Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315), a China-based Contract Research Organization (CRO), has announced...
China’s Betta Pharmaceuticals Advances CFT8919 for EGFR-Mutated NSCLC After NMPA Approval
Betta Pharmaceuticals Co., Ltd (SHE: 300558), a Chinese pharmaceutical company, has announced that it has...
Ascletis Pharma’s Denifanstat Advances to Phase III for Severe Acne Vulgaris Treatment
Ascletis Pharma Inc., (HKG: 1672) a China-based biotechnology company, has announced the commencement of a...
Luye Pharma’s Lurbinectedin for Metastatic SCLC Wins Macau Regulatory Nod
Luye Pharma Group (HKG: 2186), a Chinese pharmaceutical company, has announced that Macau’s medical products...
Yantai Dongcheng Pharmaceutical Gets NMPA Green Light for FAP-Targeting Radiotherapeutic Drug
Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has received approval...
Tonghua Dongbao Pharmaceuticals Secures NMPA Approval for Biosimilar Liraglutide
Tonghua Dongbao Pharmaceuticals (SHA: 600867), a Chinese pharmaceutical company, has announced that it has received...
Simcere Pharmaceutical’s SIM0501 Receives FDA Approval for Advanced Solid Tumor Clinical Trial
Simcere Pharmaceutical Group (HKG: 2096) has announced that it has received clinical trial approval from...
AstraZeneca Halts Late-Stage Trials for Lokelma in Hyperkalemia Due to Timing and Event Rate Issues
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, has announced the termination of two...